vs
EXACT SCIENCES CORP（EXAS）与北极星（PII）财务数据对比。点击上方公司名可切换其他公司
北极星的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.7B vs $878.4M），北极星净利率更高（-2.8% vs -9.8%，领先6.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-342.5M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -8.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
北极星公司（Polaris Inc.）是总部位于美国明尼苏达州麦地那的机动车制造企业，创立于明尼苏达州罗索，当地目前仍保留其工程研发与生产设施。公司曾通过胜利摩托子公司生产摩托车，2011年收购印第安摩托品牌后转由该子公司运营摩托业务，此前还曾生产私人水上摩托艇产品。
EXAS vs PII — 直观对比
营收规模更大
PII
是对方的1.9倍
$878.4M
营收增速更快
EXAS
高出15.1%
8.0%
净利率更高
PII
高出6.9%
-9.8%
自由现金流更多
EXAS
多$462.9M
$-342.5M
两年增速更快
EXAS
近两年复合增速
-8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.7B |
| 净利润 | $-86.0M | $-47.2M |
| 毛利率 | 70.1% | 20.2% |
| 营业利润率 | -9.4% | 76.5% |
| 净利率 | -9.8% | -2.8% |
| 营收同比 | 23.1% | 8.0% |
| 净利润同比 | 90.1% | 29.0% |
| 每股收益（稀释后） | $-0.45 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPII
| Q1 26 | — | $1.7B | ||
| Q4 25 | $878.4M | $1.9B | ||
| Q3 25 | $850.7M | $1.8B | ||
| Q2 25 | $811.1M | $1.9B | ||
| Q1 25 | $706.8M | $1.5B | ||
| Q4 24 | $713.4M | $1.8B | ||
| Q3 24 | $708.7M | $1.7B | ||
| Q2 24 | $699.3M | $2.0B |
净利润EXASPII
| Q1 26 | — | $-47.2M | ||
| Q4 25 | $-86.0M | $-303.6M | ||
| Q3 25 | $-19.6M | $-15.8M | ||
| Q2 25 | $-1.2M | $-79.3M | ||
| Q1 25 | $-101.2M | $-66.8M | ||
| Q4 24 | $-864.6M | $10.6M | ||
| Q3 24 | $-38.2M | $27.7M | ||
| Q2 24 | $-15.8M | $68.7M |
毛利率EXASPII
| Q1 26 | — | 20.2% | ||
| Q4 25 | 70.1% | 20.0% | ||
| Q3 25 | 68.6% | 20.7% | ||
| Q2 25 | 69.3% | 19.4% | ||
| Q1 25 | 70.8% | 16.0% | ||
| Q4 24 | 69.0% | 20.4% | ||
| Q3 24 | 69.4% | 20.6% | ||
| Q2 24 | 69.8% | 21.6% |
营业利润率EXASPII
| Q1 26 | — | 76.5% | ||
| Q4 25 | -9.4% | -16.7% | ||
| Q3 25 | -3.0% | 1.1% | ||
| Q2 25 | -0.3% | -0.7% | ||
| Q1 25 | -13.6% | -2.4% | ||
| Q4 24 | -122.8% | 3.7% | ||
| Q3 24 | -5.6% | 3.8% | ||
| Q2 24 | -3.8% | 6.1% |
净利率EXASPII
| Q1 26 | — | -2.8% | ||
| Q4 25 | -9.8% | -15.8% | ||
| Q3 25 | -2.3% | -0.9% | ||
| Q2 25 | -0.1% | -4.3% | ||
| Q1 25 | -14.3% | -4.3% | ||
| Q4 24 | -121.2% | 0.6% | ||
| Q3 24 | -5.4% | 1.6% | ||
| Q2 24 | -2.3% | 3.5% |
每股收益（稀释后）EXASPII
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $-0.45 | $-5.34 | ||
| Q3 25 | $-0.10 | $-0.28 | ||
| Q2 25 | $-0.01 | $-1.39 | ||
| Q1 25 | $-0.54 | $-1.17 | ||
| Q4 24 | $-4.69 | $0.18 | ||
| Q3 24 | $-0.21 | $0.49 | ||
| Q2 24 | $-0.09 | $1.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $282.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $750.4M |
| 总资产 | $5.9B | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPII
| Q1 26 | — | $282.0M | ||
| Q4 25 | $964.7M | $138.0M | ||
| Q3 25 | $1.0B | $335.5M | ||
| Q2 25 | $858.4M | $324.3M | ||
| Q1 25 | $786.2M | $291.7M | ||
| Q4 24 | $1.0B | $287.8M | ||
| Q3 24 | $1.0B | $291.3M | ||
| Q2 24 | $946.8M | $322.7M |
总债务EXASPII
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $2.1B |
股东权益EXASPII
| Q1 26 | — | $750.4M | ||
| Q4 25 | $2.4B | $828.4M | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $3.2B | $1.3B | ||
| Q2 24 | $3.2B | $1.3B |
总资产EXASPII
| Q1 26 | — | $5.2B | ||
| Q4 25 | $5.9B | $4.9B | ||
| Q3 25 | $5.9B | $5.3B | ||
| Q2 25 | $5.8B | $5.4B | ||
| Q1 25 | $5.7B | $5.5B | ||
| Q4 24 | $5.9B | $5.5B | ||
| Q3 24 | $6.7B | $5.6B | ||
| Q2 24 | $6.7B | $5.7B |
负债/权益比EXASPII
| Q1 26 | — | — | ||
| Q4 25 | — | 1.82× | ||
| Q3 25 | — | 1.13× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-342.5M |
| 自由现金流率自由现金流/营收 | 13.7% | -20.6% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $168.0M |
8季度趋势，按日历期对齐
经营现金流EXASPII
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $178.7M | ||
| Q3 25 | $219.9M | $158.8M | ||
| Q2 25 | $89.0M | $320.3M | ||
| Q1 25 | $30.8M | $83.2M | ||
| Q4 24 | $47.1M | $206.3M | ||
| Q3 24 | $138.7M | $21.0M | ||
| Q2 24 | $107.1M | $146.3M |
自由现金流EXASPII
| Q1 26 | — | $-342.5M | ||
| Q4 25 | $120.4M | $114.0M | ||
| Q3 25 | $190.0M | $116.7M | ||
| Q2 25 | $46.7M | $279.8M | ||
| Q1 25 | $-365.0K | $47.6M | ||
| Q4 24 | $10.7M | $137.3M | ||
| Q3 24 | $112.6M | $-32.4M | ||
| Q2 24 | $71.2M | $79.1M |
自由现金流率EXASPII
| Q1 26 | — | -20.6% | ||
| Q4 25 | 13.7% | 5.9% | ||
| Q3 25 | 22.3% | 6.3% | ||
| Q2 25 | 5.8% | 15.1% | ||
| Q1 25 | -0.1% | 3.1% | ||
| Q4 24 | 1.5% | 7.8% | ||
| Q3 24 | 15.9% | -1.9% | ||
| Q2 24 | 10.2% | 4.0% |
资本支出强度EXASPII
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 3.4% | ||
| Q3 25 | 3.5% | 2.3% | ||
| Q2 25 | 5.2% | 2.2% | ||
| Q1 25 | 4.4% | 2.3% | ||
| Q4 24 | 5.1% | 3.9% | ||
| Q3 24 | 3.7% | 3.1% | ||
| Q2 24 | 5.1% | 3.4% |
现金转化率EXASPII
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 19.46× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PII
暂无分部数据
